Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study

(2014) Wai-Kay Seto et al.   GUT

Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study

(2014) Wai-Kay Seto et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatitis B virus genotypes: Global distribution and clinical importance

(2014) Mustafa Sunbul   WORLD JOURNAL OF GASTROENTEROLOGY

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency

(2013) Danny Ka-Ho Wong et al.   Clinical Gastroenterology and Hepatology

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

(2013) Gi-Ae Kim et al.   GUT

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

(2013) Wai-Kay Seto et al.   HEPATOLOGY

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment

(2013) Wai-Kay Seto et al.   JOURNAL OF HEPATOLOGY

N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape

(2013) De-Min Yu et al.   JOURNAL OF HEPATOLOGY

Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels

(2012) Teresa Pollicino et al.   HEPATOLOGY

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance

(2012) Wai-Kay Seto et al.   HEPATOLOGY

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

(2012) Tetsuya Hosaka et al.   JOURNAL OF GASTROENTEROLOGY

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely

(2012) Stéphane Chevaliez et al.   JOURNAL OF HEPATOLOGY

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

(2011) Man-Fung Yuen et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

(2010) E. Jenny Heathcote et al.   GASTROENTEROLOGY

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

(2010) Karsten Wursthorn et al.   HEPATOLOGY

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY

Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

(2010) Alexander J.V. Thompson et al.   HEPATOLOGY

Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus

(2009) Josephine Simonetti et al.   HEPATOLOGY

HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma

(2008) Man–Fung Yuen et al.   GASTROENTEROLOGY